Item 8.01 Other Events.

On October 17, 2021, Ionis Pharmaceuticals, Inc. issued a press release announcing that Ionis' partner, Biogen, announced topline results from its placebo-controlled pivotal Phase 3 VALOR study of tofersen, an investigational antisense medicine being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS).

A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.

Exhibit No. Description

   99.1     Press Release dated October 17, 2021.

    104     Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses